Ankasa Regenerative Therapeutics Gets $8.5M For Stem Cells

La Jolla-based Ankasa Regenerative Therapeutics, a company developing stem-cell based products aimed at organ and tissue regrowth, repair, and healing, has raised $8.5M in a Series A funding, the company said this morning. The funding was led by Avalon Ventures, and also included Hereaus Medical and Correlation Ventures. the company said the funding is the first tranche of a $17M, Series A round of funding. Ankasa said its is focused on development of the stem cell growth factor WNT3A, which is found in humans and functions in the maintenance of bone growth and repair. The startup is led by Sanford J. Madigan. More information »